300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
28 Mar 2024
34m
STAT · Science
The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
299: Live! From the STAT Breakthrough Summit East
21 Mar 2024
33m
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
14 Mar 2024
35m
297: VC turmoil, GLP-1 competition, & the war on recovery
07 Mar 2024
27m
296: Legal insider trading, booming biotech stocks, & the next GLP-1
29 Feb 2024
24m
295: Humira’s legacy, CEO symbolism, and genomic surgery
22 Feb 2024
34m
294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking
15 Feb 2024
30m
293: AI in medicine, detangling hype, and Icelandic DNA
08 Feb 2024
32m
292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon
01 Feb 2024
35m
291: The plight of the VC, Gilead's latest setback, & more M&A
25 Jan 2024
31m
290: Biotech layoffs, slumping stocks, and a 2024 preview
18 Jan 2024
42m
289: Live! From #JPM24
11 Jan 2024
28m
287: 2023 in review, CEO report cards, and a look at the year ahead
21 Dec 2023
27m
286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future
14 Dec 2023
34m
285: CRISPR history, biotech struggles, & a big week for deals
07 Dec 2023
36m
284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
30 Nov 2023
28m
283: A CRISPR milestone, algorithms amok, & biotech mixology
16 Nov 2023
30m
From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?
13 Nov 2023
29m
282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
09 Nov 2023
37m
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
02 Nov 2023
32m
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.